Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the “SERENA study”, a randomized, double-blind, placebo-controlled trial

• DOI: 10.1007/s12020-019-01958-1
• Publication Date: 2019-05-25T14:03:47Z
• Authors: G. Mantovani; A. M. Isidori; C. Moretti; C. Di Dato; E. Greco; P. Ciolli; M. Bonomi; L. Petrone; A. Fumarola; G. Campagna; G. Vannucchi; S. Di Sante; C. Pozza; A. Faggiano; A. Lenzi; E. Giannetta
• Keywords: Autoimmune thyroiditis; Fetal risk; L-selenomethionine; Maternal complications; Adult; Thyroid Diseases; Autoimmune Diseases; Trace Elements; 3. Good health; Pregnancy Complications; Selenium; 03 medical and health sciences; 0302 clinical medicine; autoimmune thyroiditis; fetal risk; L-selenomethionine; maternal complications; Double-Blind Method; Pregnancy; Dietary Supplements; Humans; Female; Autoantibodies

Selenium is frequently in nutraceuticals for pregnancy, given its role on fertility and thyroid metabolism. However, most evidence rise from non-controlled studies. We aimed to evaluate the protective effect of selenium against autoimmunity during after pregnancy. A multicenter, randomized, double-blind, placebo-controlled trial was performed promoted by Young Italian Endocrinologists Group (EnGioI)—Italian Society Endocrinology. Forty-five women with thyroiditis pregnancy were enrolled randomly assigned L-selenomethionine (L-Se-Met) 83 mcg/day or placebo (PLB) evaluated at 10 ± 2 (T1), 36 weeks gestation (T2) 6 months delivery (postpartum, PP). measured a significant reduction autoantibodies L-Se-Met group [at PP: TgAb 19.86 (11.59–52.60), p < 0.01; TPOAb 255.00 (79.00–292.00), 0.01], an antibodies titer's rebound PLB (TgAb 151.03 182.9, 441.28 512.18, 0.01). increase selenemia T2 (91.33 25.49; 0.01) PP (93.55 23.53; = 0.02). Two miscarriage occurred PLB. No differences found volume, echogenicity, quality life, maternal/fetal complications. SERENA study demonstrated beneficial supplementation autoantibody titer postpartum recurrence.